Retatrutide: What the Weight Loss Evidence and FDA Status Actually Show

Interest in retatrutide is understandable. In a published Phase 2 obesity trial, participants receiving the highest studied amount lost an average of 24.2 percent of their starting body weight after 48 weeks. More recently, Lilly reported that participants in the Phase 3 TRIUMPH-1 trial lost an average of 28.3 percent after 80 weeks at the highest studied level.

Those numbers are striking, but they need context. Retatrutide remains an experimental drug. Some Phase 3 results have been released only as manufacturer-reported topline findings, not as complete peer-reviewed publications. Its long-term risks, real-world safety, effectiveness after several years, and outcomes after treatment is stopped are still being studied.

What is retatrutide and how does it work?

Retatrutide is a single experimental molecule that activates the GIP, GLP-1, and glucagon receptors. Because it targets three receptor systems, it is often described as a triple hormone receptor agonist or triple agonist.

The three targets are:

• GLP-1, or glucagon-like peptide-1, is involved in appetite, fullness, insulin signaling, and the movement of food through the stomach.
• GIP, or glucose-dependent insulinotropic polypeptide, also influences insulin release, appetite regulation, and how the body handles nutrients.
• Glucagon is normally associated with raising blood sugar, but glucagon receptor activity can also affect liver metabolism, fat processing, and energy expenditure. Researchers are studying whether carefully combining glucagon activity with GLP-1 and GIP activity can produce greater metabolic effects than targeting GLP-1 alone.

This third pathway is the major difference between retatrutide and tirzepatide. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity. Semaglutide targets the GLP-1 receptor rather than using a dual or triple receptor design.

Calling retatrutide a peptide is broadly reasonable because it is a peptide-based hormone receptor agonist. Calling it a supplement is not. It is a pharmaceutical drug candidate being evaluated in controlled clinical trials.

How much weight did people lose on retatrutide in trials?

Retatrutide produced average weight reductions of up to 24.2 percent in the published Phase 2 obesity trial and 28.3 percent in Lilly's Phase 3 TRIUMPH-1 topline results.

Phase 2 obesity trial

The Phase 2 trial enrolled adults with obesity, or overweight with a weight-related condition, who did not have type 2 diabetes. Results were published in the New England Journal of Medicine in 2023.

Weight loss increased over time and varied across the study groups. At the highest studied level, the average reduction was 17.5 percent after 24 weeks and 24.2 percent after 48 weeks. The placebo group lost substantially less weight.

The study also found that weight loss had not clearly reached a plateau at 48 weeks in the higher-level groups. That suggested additional weight loss might occur with longer treatment, but the Phase 2 study alone could not establish how much more would occur or whether the effect would be maintained safely over several years.

Phase 3 TRIUMPH-1

TRIUMPH-1 is a randomized, double-blind, placebo-controlled Phase 3 trial involving adults with obesity or overweight, at least one weight-related health condition, and no diabetes. The ClinicalTrials.gov identifier is NCT05929066.

According to Lilly's May 2026 topline announcement, average weight change after 80 weeks was:

• 19.0 percent in the lowest retatrutide group
• 25.9 percent in the middle group
• 28.3 percent in the highest group
• 2.2 percent with placebo

Participants started at an average weight of about 248.5 pounds. The average loss in the highest group was approximately 70.3 pounds.

In that highest group, 45.3 percent of participants lost at least 30 percent of their starting body weight. In a prespecified extension involving participants who began with a body mass index of at least 35, the reported average reduction reached 30.3 percent after 104 weeks.

These findings are important, but the May 2026 figures came from a Lilly news release. The complete peer-reviewed TRIUMPH-1 publication will provide more detail about statistical methods, missing data, treatment discontinuation, serious adverse events, participant subgroups, and how the results should be interpreted. Lilly stated that additional results would be presented at medical meetings and submitted for publication.

Other Phase 3 studies

The broader TRIUMPH program is examining retatrutide in several populations, including people with obesity and type 2 diabetes, severe obesity with cardiovascular disease, knee osteoarthritis, obstructive sleep apnea, and other obesity-related conditions.

In July 2026, Lilly announced positive topline findings from TRIUMPH-2 and TRIUMPH-3. TRIUMPH-2 studied people with obesity or overweight and type 2 diabetes. TRIUMPH-3 studied people with severe obesity and established cardiovascular disease, with or without diabetes. Lilly said detailed findings would be presented later and published in peer-reviewed journals.

Lilly also reported Phase 3 results from TRIUMPH-4, a study involving obesity or overweight and knee osteoarthritis. In that study, the company reported average weight loss of up to 28.7 percent, alongside improvement in knee pain. Those findings were also initially released as topline manufacturer data.

How does retatrutide compare to tirzepatide and semaglutide?

Retatrutide has produced greater average weight loss in separate trials than the original pivotal obesity trials of tirzepatide and semaglutide, but separate trials cannot prove that one drug is superior to another.

In the STEP 1 trial of semaglutide for obesity, participants receiving semaglutide lost an average of 14.9 percent of their starting weight after 68 weeks, compared with 2.4 percent with placebo.

In the SURMOUNT-1 trial of tirzepatide, average weight reduction reached 19.5 percent and 20.9 percent in the two highest study groups after 72 weeks, compared with 3.1 percent with placebo.

Retatrutide reached 24.2 percent at 48 weeks in Phase 2 and 28.3 percent at 80 weeks in the TRIUMPH-1 topline findings.

That does not establish an apples-to-apples ranking. The studies differed in duration, participant characteristics, starting weight, trial design, statistical analysis, treatment completion, and other details.

A direct Phase 3 trial called TRIUMPH-5 is comparing retatrutide with tirzepatide in adults with obesity. That head-to-head study is designed to provide a more reliable comparison than placing results from unrelated trials side by side. Its ClinicalTrials.gov identifier is NCT06662383.

The fairest summary is that retatrutide has produced unusually large average weight reductions in its studies, but it has not yet been proven superior to tirzepatide in a completed, published head-to-head trial.

It is also important to distinguish brand names from active ingredients. Semaglutide is sold as Wegovy for chronic weight management and as Ozempic for type 2 diabetes. Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Retatrutide does not currently have an approved consumer brand because it has not been approved for public use.

What are the side effects of retatrutide?

The most common reported side effects of retatrutide have been gastrointestinal, especially nausea, diarrhea, constipation, and vomiting.

In the Phase 2 obesity trial, gastrointestinal reactions occurred mainly during treatment escalation, were generally mild to moderate, and were more frequent in higher-level groups. Gastrointestinal problems were also the most common reason participants discontinued treatment.

The Phase 2 study also observed a dose-related increase in heart rate through approximately 24 weeks, followed by a decline later in the trial. The long-term clinical importance of that heart-rate effect remains part of the broader safety question.

In TRIUMPH-1, Lilly reported the following adverse-event rates in the highest retatrutide group:

• Nausea, 42.4 percent
• Diarrhea, 32.0 percent
• Constipation, 26.1 percent
• Vomiting, 25.3 percent

The corresponding placebo rates were 14.8 percent, 13.5 percent, 10.9 percent, and 4.8 percent.

Lilly also reported dysesthesia, an abnormal skin sensation such as tingling, burning, altered sensitivity, or unusual touch sensation, in 12.5 percent of participants in the highest group, compared with 0.9 percent receiving placebo. Urinary tract infections were reported in 8.4 percent of that group and 5.3 percent of the placebo group. Most of those events were described as mild to moderate.

Discontinuation because of adverse events occurred in 11.3 percent of participants in the highest retatrutide group and 4.9 percent of the placebo group.

The Phase 3 diabetes study TRANSCEND-T2D-1 also identified nausea, diarrhea, and vomiting as the most common adverse events. Lilly reported that these events occurred mainly during treatment escalation.

Is retatrutide FDA approved?

No, retatrutide is not FDA approved as of July 2026. It has not been approved for weight loss, diabetes, fatty liver disease, sleep apnea, osteoarthritis, cardiovascular disease, or any other condition. Lilly continues to describe it as investigational.

On July 23, 2026, Lilly said it planned to submit a Biologics License Application to the FDA in the first quarter of 2027. A planned application is not an approval. After an application is filed, the FDA must review the evidence relating to effectiveness, manufacturing, product quality, labeling, and safety before deciding whether the drug may be marketed.

There is no guaranteed approval date. The FDA could approve the application, request additional information, require more analysis, delay a decision, or decline approval.

Can you get retatrutide legally right now?

In the United States, legitimate retatrutide is currently available only through authorized Lilly clinical trials.

A physician cannot write an ordinary prescription for commercial retatrutide because no FDA-approved retatrutide product exists. Lilly states that no one should take a product claiming to be retatrutide outside one of its sponsored clinical trials.

The FDA has stated specifically that retatrutide cannot be used in compounding under federal law. The agency also says retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.

FDA warning letters have targeted businesses selling products labeled as compounded retatrutide or as research chemicals. The agency has said these products are unapproved new drugs and has warned that injectable products from unverified sellers can create serious risks involving contamination, potency, sterility, identity, and labeling.

What are the risks and unknowns?

The biggest unknown is not whether retatrutide can produce weight loss, but whether its benefits remain favorable when used across much larger populations and over many years. Several major questions remain.

Long-term safety is still limited

The published obesity trial lasted 48 weeks. TRIUMPH-1 extended the main analysis to 80 weeks, with a smaller prespecified extension reaching 104 weeks. That is valuable evidence, but it is not the same as five-year or ten-year safety data.

Full Phase 3 publications are still needed

Some of the most impressive 2025 and 2026 findings have been announced through Lilly news releases. Topline releases can accurately report major endpoints, but they do not provide the full detail of a peer-reviewed paper, regulatory review, or final prescribing label.

Cardiovascular outcomes are not yet settled

Improvements in weight, blood pressure, waist circumference, triglycerides, and inflammatory markers are encouraging. They do not automatically prove that retatrutide prevents heart attacks, strokes, heart failure, kidney failure, or premature death. Dedicated outcome studies are required to answer those questions.

Weight regain after stopping remains a concern

Long-term experience with approved obesity medications suggests that obesity often requires ongoing management. The extent and speed of weight regain after retatrutide is stopped will need to be established directly through maintenance and withdrawal studies.

Very large weight loss has nutritional implications

Substantial weight reduction can include loss of both fat mass and lean tissue. Clinical care may need to address nutrition, protein intake, resistance exercise, gallbladder risk, gastrointestinal tolerance, and the preservation of muscle and physical function. Retatrutide-specific long-term body-composition data are still developing.

Online products are not the studied drug

A vial sold online with retatrutide printed on the label is not automatically the same material used in Lilly's clinical trials. The studied drug is manufactured under controlled pharmaceutical conditions, tested for identity and purity, administered under a trial protocol, and monitored by clinical investigators. An online research product may contain the wrong amount, the wrong substance, contaminants, or no active ingredient at all.

Retatrutide FAQ

Is retatrutide the same as Mounjaro?

No. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1, and glucagon receptors and remains investigational.

Is retatrutide stronger than Ozempic?

Retatrutide has produced greater average weight loss in separate obesity trials than semaglutide produced in the STEP 1 trial, but the drugs were not compared in the same study. Cross-trial comparisons cannot prove that retatrutide is stronger or better for a particular patient.

Is retatrutide a GLP-1 drug?

It includes GLP-1 receptor activity, but it is more accurately described as a triple GIP, GLP-1, and glucagon receptor agonist.

Does retatrutide burn fat?

Retatrutide has produced substantial reductions in body weight and fat mass in clinical research, but fat burner is an oversimplified marketing term. Its effects involve appetite, food intake, glucose regulation, and broader metabolic signaling.

When will retatrutide be available?

There is no confirmed public availability date. Lilly announced plans to submit an FDA application in the first quarter of 2027, but availability would depend on FDA review and approval.

Can a compounding pharmacy make retatrutide?

The FDA says retatrutide cannot be used in compounding under federal law. Products marketed as compounded retatrutide are not FDA approved and are not equivalent to the investigational drug used in Lilly trials.

The bottom line

Retatrutide may become one of the most effective pharmaceutical treatments developed for obesity, but it is not there yet from a regulatory standpoint.

The evidence has moved beyond early laboratory speculation. Retatrutide has produced substantial weight loss in a peer-reviewed Phase 2 trial, followed by strong reported findings across Lilly's Phase 3 development program. At the same time, it remains investigational, has no approved prescribing label, and cannot legally be purchased as a compounded substitute in the United States.

Anyone considering medical treatment for obesity should discuss approved options with a licensed clinician who can evaluate medical history, current medications, cardiovascular and metabolic risks, treatment goals, and appropriate monitoring. Retatrutide should not be treated as a supplement, a do-it-yourself peptide, or a shortcut around regulated medical care.